摘要
目的研究阿托伐他汀对急性冠脉综合征(ACS)患者冠脉介入治疗术(PCI)后血清高敏C反应蛋白(hs-CRP)和单核细胞过氧化物酶增殖体激活型受体γ(PPARγ)的影响。方法选择2009年2-9月在该院心内科收治的84例接受PCI的ACS患者,随机平均分为2组,对照组(42例)给予常规药物治疗,研究组(42例)在常规治疗的基础上加用阿托伐他汀20mg口服治疗,分别检测术前、术后24h和术后3d的血清hs-CRP和PPARγ水平。结果研究组术后血清hs-CRP水平显著低于同期对照组(P<0.05);研究组术后血清PPARγ水平显著高于同期对照组(P<0.05)。结论阿托伐他汀可以显著降低PCI术后血清hs-CRP水平,并且可以显著提高血清PPARγ水平,疗效确切。
Objective To study atorvastatin statins on patients with acute coronary syndrome（ACS）, pereutaneous coronary interven- tion therapy （PCI）, serum high-sensitivity c-reactive protein （hs-CRP）, and mononuclear cells in peroxisome proliferator activated receptorγ （PPARγ）. Methods 84 cases were treated in hospital of Cardiology in February 2009 to September 2009 patients with ACS undergoing PCI were randomly divided into two groups, control group （42 cases） treated with conventional medication, the study group（42 cases were detected by preoperative） in the conventional therapy plus statin 20rag oral treatment with atorvastatin, the 3d 24h after surgery and postoperative serum hs-CRP and PPARγ levels. Results The study group postoperative serum hs- CRP levels were significantly lower than the control group （P〈0.05）; study group postoperative serum PPARγ levels were signifi- cantly higher than the corresponding control group （P〈0.05）. Conclusions Atorvastatin significantly lower after PCI serum hs-CRP levels and can significantly improve the level of serum PPARγ, and effective.
出处
《中外医疗》
2012年第21期6-7,共2页
China & Foreign Medical Treatment
